November 20, 2017

Wallingford drugmaker's layoffs to continue into 2018

[This story has been updated.]

Wallingford drugmaker Bristol-Meyers Squibb, which is planning to close facilities in the state by the end of 2018, is phasing in 29 more layoffs through January.

That will bring the company's total Connecticut layoff count to 113 since February, according to the Connecticut Department of Labor (DOL).

In December of 2016, the company announced it would close up shop entirely at its 5 Research Parkway operations, where at the time it employed about 700 people.

Since then, the pharmaceutical company has notified DOL of various layoffs throughout the year. The latest notice indicates 25 employees will be let go on Dec. 19 and four on Jan. 9.

The December layoffs include five research scientists, three operations managers, and a number of technicians, drug specialists and others. The January layoffs include three principal analysts and a group leader.

In late 2016, the company said it would invest in new construction in Lawrenceville and New Brunswick, N.J.; and continue to expand its Devens, Mass., biologics campus. It is also expanding in Cambridge and the San Francisco Bay area.

"We continue to evaluate the roles and work within our functions based on changes to the needs of our business, our geographic presence and broader decisions in support of our company transformation," said Sarah Koenig, director of corporate affairs. "Many of the roles from Connecticut will transition to other U.S. locations. The specific details are still evolving. We remain on schedule to close the Wallingford facility at the end of 2018."

Free E-Newsletters

Sign up now for our daily and weekly
e-newsletters! Click Here

Today's Poll Can Greater Hartford support another regional shopping center like the Outlets Shoppes at Rentschler Field?<>
Most Popular on Facebook
Copyright 2017 New England Business Media